Autoimmune hepatitis

Current Pediatric Reviews

Volumn 10, Issue 4, 2014, Pages 268-274

  Longhi, Maria Serena ^a   Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune hepatitis; Immunosuppression; Interface hepatitis; Regulatory T cells

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; LIVER KIDNEY MICROSOMAL ANTIBODY TYPE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; GENETICS; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; PATHOLOGY; PROGNOSIS; SMOOTH MUSCLE FIBER;

ANTIBODIES, ANTINUCLEAR; CHILD; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; MYOCYTES, SMOOTH MUSCLE; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 84924915176     PISSN: 15733963     EISSN: 18756336     Source Type: Journal    
DOI: 10.2174/1573396310666141114230147     Document Type: Article

References (54)

1. [1] Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354(1): 54-66.
2. [2] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51(6): 2193-213.
3. [3] Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1(8528): 292-4.
4. [4] Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35(3): 658-64.
5. [5] Boberg M, Angerbauer R, Kanhai WK, et al. Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metab Dispos 1998; 26(7): 640-52.
6. [6] Bischoff H, Angerbauer R, Boberg M, et al. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. Atherosclerosis 1998;139 Suppl 1: S7-13.
7. [7] Primo J, Merino C, Fernandez J, Moles JR, Llorca P, Hinojosa J. [Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)]. Gastroenterol Hepatol 2004; 27(4): 239-43.
8. [8] Whalley S, Puvanachandra P, Desai A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med 2007; 7(2): 119-24.
9. [9] Campo L, Addario L, Buratti M, et al. Biological monitoring of exposure to polycyclic aromatic hydrocarbons by determination of unmetabolized compounds in urine. Toxicol Lett 2006; 162(2-3): 132-8.
10. [10] Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol Immunol 2006; 43(10): 1509-18.
11. [11] McFarlane IG. Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002; 22(4): 317-24.
12. [12] Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25(3): 541-7.
13. [13] Sottero B, Gamba P, Longhi M, et al. Expression and synthesis of TGFbeta1 is induced in macrophages by 9-oxononanoyl cholesterol, a major cholesteryl ester oxidation product. Biofactors 2005; 24(1-4): 209-16.
14. [14] Oettinger R, Brunnberg A, Gerner P, Wintermeyer P, Jenke A, Wirth S. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005; 24(1): 79-84.
15. [15] Grammatikopoulos A, Cirllo F, Zen Y, Davies E, Vergani D, Mieli-Vergani G. Prevalence and significance of raised IgG4 in paediatric autoimmune liver disease; a retrospective study. Hepatology 2011; 54, 4 (suppl): 701A.
16. [16] Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33(3): 544-53.
17. [17] Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31(5): 929-38.
18. [18] Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41(4): 677-83.
19. [19] Mieli-Vergani G, Heller S, Jara P, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009; 49(2): 158-64.
20. [20] Muratori L, Parola M, Ripalti A, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000; 46(4): 553-61.
21. [21] Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116(3): 643-9.
22. [22] Palioura S, Sherrer RL, Steitz TA, Soll D, Simonovic M. The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation. Science 2009; 325(5938): 321-5.
23. [23] Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006; 43(5): 629-34.
24. [24] Yeoman AD, Longhi MS, Heneghan MA. Review article: the moderm management of autoimmune hepatitis. Aliment Pharmacol Ther 2010; 31(8): 771-87.
25. [25] Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30(2): 222-7.
26. [26] Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43(5): 635-9.
27. [27] Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135(1): 111-4.
28. [28] Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90(3): 455-9.
29. [29] Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33(3): 371-5.
30. [30] Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; 51(1):156-60.
31. [31] Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18(5): 321-6.
32. [32] Hennes EM, Oo YH, Schramm C, Denzer U, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103(12): 3063-70.
33. [33] Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004; 40(1): 3-7.
34. [34] Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005; 5(5): 1085-9.
35. [35] Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48(1): 97-102.
36. [36] Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum 2005; 35(1): 49-56.
37. [37] Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009; 43(4): 350-6.
38. [38] Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250-9.
39. [39] Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol 1994; 41(2): 146-50.
40. [40] Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992; 67(12): 1447-53.
41. [41] Ismail NH, Portmann B, Hussain M, Williams R, Mieli-Vergani G, Vergani D. Immunohistochemical evidence for Th1 cytokine pre- dominance in the liver of children with autoimmune hepatitis. Hepatology 1999; 1069.
42. [42] Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130(3): 868-82.
43. [43] Longhi MS, Hussain MJ, Bogdanos DP, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007; 46(2): 472-84.
44. [44] Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009; 50(1): 130-42.
45. [45] Vento S, Hegarty JE, Bottazzo G, Macchia E, Williams R, Eddleston AL. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984; 1(8388): 1200-4.
46. [46] Nouri-Aria KT, Lobo-Yeo A, Vergani D, Mieli-Vergani G, Eddleston AL, Mowat AP. T suppressor cell function and number in children with liver disease. Clin Exp Immunol 1985; 61(2): 283-9.
47. [47] Hodgson HJ, Wands JR, Isselbacher KJ. Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci U S A 1978; 75(3): 1549-53.
48. [48] Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004; 41(1): 31-7.
49. [49] Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005; 25(1): 63-71.
50. [50] Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176(7): 4484-91.
51. [51] Liberal R, Grant CR, Holder B, et al. The impaired immune regulation of autoimmune hepatitis is linked to a defective Galectin-9/Tim-3 pathway. Hepatology 2012.
52. [52] Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008; 47(2): 581-91.
53. [53] Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology 2011; 53(2): 536-47.
54. [54] Zhao L, Tang Y, You Z, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011; 6(4): e18909.